Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03778957




Registration number
NCT03778957
Ethics application status
Date submitted
28/11/2018
Date registered
19/12/2018
Date last updated
22/05/2024

Titles & IDs
Public title
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
Scientific title
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)
Secondary ID [1] 0 0
2018-002134-20
Secondary ID [2] 0 0
D933GC00001
Universal Trial Number (UTN)
Trial acronym
EMERALD-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatocellular Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Liver

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Durvalumab
Treatment: Drugs - Bevacizumab
Other interventions - Placebo
Treatment: Surgery - Transarterial Chemoembolization (TACE)

Experimental: Arm A - Transarterial Chemoembolization (TACE) in combination with Durvalumab

Experimental: Arm B - Transarterial Chemoembolization (TACE) in combination with Durvalumab and Bevacizumab

Placebo Comparator: Arm C - Transarterial Chemoembolization (TACE) in combination with Placebos


Treatment: Drugs: Durvalumab
Durvalumab IV (intravenous)

Treatment: Drugs: Bevacizumab
Bevacizumab IV (intravenous)

Other interventions: Placebo
Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)

Treatment: Surgery: Transarterial Chemoembolization (TACE)
TACE (chemo and embolic agent injection into the hepatic artery)
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Intervention code [3] 0 0
Treatment: Surgery
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS) for Arm B vs Arm C
Timepoint [1] 0 0
Approximately 5 years
Secondary outcome [1] 0 0
Progression Free Survival (PFS) for Arm A vs Arm C
Timepoint [1] 0 0
Approximately 5 years
Secondary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Approximately 5 years
Secondary outcome [3] 0 0
Health status/quality of life measured by European Organization for Research and Treatment of Cancer (EORTC) 30-item core quality of life questionnaire (QLQ-C30)
Timepoint [3] 0 0
Approximately 5 years
Secondary outcome [4] 0 0
Disease-related symptoms measured by European Organization for Research and Treatment of Cancer (EORTC) 18-item hepatocellular cancer health-related quality of life questionnaire (QLQ-HCC18)
Timepoint [4] 0 0
Approximately 5 years

Eligibility
Key inclusion criteria
Key

- No evidence of extrahepatic disease

- Disease not amenable to curative surgery or transplantation or curative ablation but
disease amenable to TACE

- Child-Pugh score class A to B7 and Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1 at enrollment

- Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria

- Adequate organ and marrow function

Key
Minimum age
18 Years
Maximum age
110 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

- Any history of nephrotic or nephritic syndrome

- Clinically significant cardiovascular disease or history of arterioembolic event
including a stroke or myocardial infarction, unstable angina, cerebrovascular
accident, or transient ischemic attack within 6 months prior to randomization

- Any prior or current evidence of coagulopathy or bleeding diathesis or patients who
had any kind of surgery in the past 28 days (biopsies are exempt from this exclusion)

- History of abdominal fistula or GI perforation, non healed gastric ulcer that is
refractory to treatment, or active GI bleeding within 6 months prior to enrollment

- Patients with Vp3 and Vp4 portal vein thrombosis on baseline imaging are excluded

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/11/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/08/2026
Actual
Sample size
Target
Accrual to date
Final
724
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Benowa
Recruitment hospital [2] 0 0
Research Site - Box Hill
Recruitment hospital [3] 0 0
Research Site - Camperdown
Recruitment hospital [4] 0 0
Research Site - Clayton
Recruitment hospital [5] 0 0
Research Site - Herston
Recruitment hospital [6] 0 0
Research Site - Liverpool
Recruitment hospital [7] 0 0
Research Site - Melbourne
Recruitment postcode(s) [1] 0 0
4217 - Benowa
Recruitment postcode(s) [2] 0 0
3128 - Box Hill
Recruitment postcode(s) [3] 0 0
2050 - Camperdown
Recruitment postcode(s) [4] 0 0
3168 - Clayton
Recruitment postcode(s) [5] 0 0
4029 - Herston
Recruitment postcode(s) [6] 0 0
2170 - Liverpool
Recruitment postcode(s) [7] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Hawaii
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
Nebraska
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oregon
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
South Dakota
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
West Virginia
Country [25] 0 0
United States of America
State/province [25] 0 0
Wisconsin
Country [26] 0 0
Brazil
State/province [26] 0 0
Barretos
Country [27] 0 0
Brazil
State/province [27] 0 0
Florianópolis
Country [28] 0 0
Brazil
State/province [28] 0 0
Porto Alegre
Country [29] 0 0
Brazil
State/province [29] 0 0
Rio de Janeiro
Country [30] 0 0
Brazil
State/province [30] 0 0
Santa Maria
Country [31] 0 0
Brazil
State/province [31] 0 0
Sao Paulo
Country [32] 0 0
Brazil
State/province [32] 0 0
São José do Rio Preto
Country [33] 0 0
Brazil
State/province [33] 0 0
Vitória
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
China
State/province [36] 0 0
Beijing
Country [37] 0 0
China
State/province [37] 0 0
Changchun
Country [38] 0 0
China
State/province [38] 0 0
Changsha
Country [39] 0 0
China
State/province [39] 0 0
Chengdu
Country [40] 0 0
China
State/province [40] 0 0
Fuzhou
Country [41] 0 0
China
State/province [41] 0 0
Guangzhou
Country [42] 0 0
China
State/province [42] 0 0
Hangzhou
Country [43] 0 0
China
State/province [43] 0 0
Harbin
Country [44] 0 0
China
State/province [44] 0 0
Hefei
Country [45] 0 0
China
State/province [45] 0 0
Nanchang
Country [46] 0 0
China
State/province [46] 0 0
Nanjing
Country [47] 0 0
China
State/province [47] 0 0
Nantong
Country [48] 0 0
China
State/province [48] 0 0
Neijiang
Country [49] 0 0
China
State/province [49] 0 0
Shanghai
Country [50] 0 0
China
State/province [50] 0 0
Shenyang
Country [51] 0 0
China
State/province [51] 0 0
Shenzhen
Country [52] 0 0
China
State/province [52] 0 0
Tianjin
Country [53] 0 0
China
State/province [53] 0 0
Wuhan
Country [54] 0 0
China
State/province [54] 0 0
Xi'an
Country [55] 0 0
China
State/province [55] 0 0
Zhengzhou
Country [56] 0 0
China
State/province [56] 0 0
Zhuhai
Country [57] 0 0
France
State/province [57] 0 0
Bobigny
Country [58] 0 0
France
State/province [58] 0 0
Clichy
Country [59] 0 0
France
State/province [59] 0 0
Grenoble cedex 9
Country [60] 0 0
France
State/province [60] 0 0
Montpellier CEDEX 5
Country [61] 0 0
France
State/province [61] 0 0
Nice Cedex 3
Country [62] 0 0
France
State/province [62] 0 0
Paris Cedex 13
Country [63] 0 0
France
State/province [63] 0 0
Pessac
Country [64] 0 0
France
State/province [64] 0 0
Toulouse Cedex 9
Country [65] 0 0
France
State/province [65] 0 0
Vandoeuvre Les Nancy
Country [66] 0 0
Hong Kong
State/province [66] 0 0
Hong Kong
Country [67] 0 0
Hong Kong
State/province [67] 0 0
Shatin
Country [68] 0 0
India
State/province [68] 0 0
Bangalore
Country [69] 0 0
India
State/province [69] 0 0
Bengaluru
Country [70] 0 0
India
State/province [70] 0 0
Hyderabad
Country [71] 0 0
India
State/province [71] 0 0
Kolkata
Country [72] 0 0
India
State/province [72] 0 0
Madurai
Country [73] 0 0
India
State/province [73] 0 0
Mumbai
Country [74] 0 0
India
State/province [74] 0 0
Nashik
Country [75] 0 0
India
State/province [75] 0 0
Pune
Country [76] 0 0
India
State/province [76] 0 0
Surat
Country [77] 0 0
India
State/province [77] 0 0
Vijayawada
Country [78] 0 0
India
State/province [78] 0 0
Vishakhapatnam
Country [79] 0 0
Italy
State/province [79] 0 0
Arezzo
Country [80] 0 0
Italy
State/province [80] 0 0
Brescia
Country [81] 0 0
Italy
State/province [81] 0 0
Milano
Country [82] 0 0
Italy
State/province [82] 0 0
Pisa
Country [83] 0 0
Japan
State/province [83] 0 0
Bunkyo-ku
Country [84] 0 0
Japan
State/province [84] 0 0
Chiba-shi
Country [85] 0 0
Japan
State/province [85] 0 0
Chuo-ku
Country [86] 0 0
Japan
State/province [86] 0 0
Fukuoka-shi
Country [87] 0 0
Japan
State/province [87] 0 0
Hiroshima-shi
Country [88] 0 0
Japan
State/province [88] 0 0
Kurume-shi
Country [89] 0 0
Japan
State/province [89] 0 0
Musashino-shi
Country [90] 0 0
Japan
State/province [90] 0 0
Nagoya-shi
Country [91] 0 0
Japan
State/province [91] 0 0
Okayama
Country [92] 0 0
Japan
State/province [92] 0 0
Osaka-shi
Country [93] 0 0
Japan
State/province [93] 0 0
Osakasayama-shi
Country [94] 0 0
Japan
State/province [94] 0 0
Sapporo-shi
Country [95] 0 0
Japan
State/province [95] 0 0
Shiwa-gun
Country [96] 0 0
Japan
State/province [96] 0 0
Tsu-shi
Country [97] 0 0
Japan
State/province [97] 0 0
Yokohama-shi
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Busan
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Daegu
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Goyang-si
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Seoul
Country [102] 0 0
Mexico
State/province [102] 0 0
Alc. Cuauhtémoc
Country [103] 0 0
Mexico
State/province [103] 0 0
Culiacan
Country [104] 0 0
Mexico
State/province [104] 0 0
Guadalajara
Country [105] 0 0
Mexico
State/province [105] 0 0
Mexico
Country [106] 0 0
Mexico
State/province [106] 0 0
Monterrey
Country [107] 0 0
Mexico
State/province [107] 0 0
Mérida
Country [108] 0 0
Mexico
State/province [108] 0 0
Tuxtla Gutierrez
Country [109] 0 0
Russian Federation
State/province [109] 0 0
Barnaul
Country [110] 0 0
Russian Federation
State/province [110] 0 0
Ekaterinburg
Country [111] 0 0
Russian Federation
State/province [111] 0 0
Kazan
Country [112] 0 0
Russian Federation
State/province [112] 0 0
Moscow
Country [113] 0 0
Russian Federation
State/province [113] 0 0
Novosibirsk
Country [114] 0 0
Russian Federation
State/province [114] 0 0
Obninsk
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Sankt-Peterburg
Country [116] 0 0
Russian Federation
State/province [116] 0 0
St. Petersburg
Country [117] 0 0
Singapore
State/province [117] 0 0
Bukit Merah
Country [118] 0 0
Spain
State/province [118] 0 0
Córdoba
Country [119] 0 0
Spain
State/province [119] 0 0
Madrid
Country [120] 0 0
Spain
State/province [120] 0 0
Pamplona
Country [121] 0 0
Spain
State/province [121] 0 0
San Sebastián(Guipuzcoa)
Country [122] 0 0
Taiwan
State/province [122] 0 0
Kaohsiung
Country [123] 0 0
Taiwan
State/province [123] 0 0
Liou Ying Township
Country [124] 0 0
Taiwan
State/province [124] 0 0
Taichung
Country [125] 0 0
Taiwan
State/province [125] 0 0
Tainan City
Country [126] 0 0
Taiwan
State/province [126] 0 0
Taipei
Country [127] 0 0
Taiwan
State/province [127] 0 0
Taoyuan City
Country [128] 0 0
Thailand
State/province [128] 0 0
Bangkok
Country [129] 0 0
Thailand
State/province [129] 0 0
Chiang Mai
Country [130] 0 0
Thailand
State/province [130] 0 0
Hat Yai
Country [131] 0 0
Thailand
State/province [131] 0 0
Khon Kaen
Country [132] 0 0
Thailand
State/province [132] 0 0
Phisanulok
Country [133] 0 0
Vietnam
State/province [133] 0 0
Hanoi
Country [134] 0 0
Vietnam
State/province [134] 0 0
Ho Chi Minh City
Country [135] 0 0
Vietnam
State/province [135] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A global study to evaluate transarterial chemoembolization (TACE) in combination with
durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma
Trial website
https://clinicaltrials.gov/ct2/show/NCT03778957
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bruno Sangro, MD
Address 0 0
Clinica Universidad de Navarra
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03778957